Blocking the interaction of human programmed death 1 (hPD-1) and its ligand hPD-L1 has been a promising immunotherapy in cancer treatment. Human PD-L1 inhibitor (Ar5Y_4, GNWDYNSQRAQLYNQ) showed a KD value of 1.38 ± 0.39 μM, comparable to the binding affinity of the cognate hPD-L1. A Surface Plasmon Resonance (SPR) competitive binding assay result indicated that Ar5Y_4 could inhibit the interaction of hPD-1/hPD-L1. Moreover, Ar5Y_4 could restore the function of Jurkat T cells which had been suppressed by stimulated HCT116 cells. Human PD-L1 inhibitor provides promising biologic candidates for cancer immunotherapy or diagnostics.
一般情况下， Human PD-L1 inhibitor Ar5Y_4 多肽 粉末应该保存在-20甚至-70摄氏度. Human PD-L1 inhibitor Ar5Y_4 多肽 溶解后应该-70摄氏度分装保存，避免反复冻融. 了解更多细节，请查阅手册:多肽溶解及保存指南
Li Q, Quan L, Lyu J, et al. Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. Oncotarget. 2016;7(40):64967-64976